Study on the linezolid prescription according to the approval of indication in a University Hospital

Document Type: Research article

Authors

1 Pharmacy Service. University Hospital “La Fe”, Valencia, Spain

2 Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Spain. Center for Public Health Research (CSISP), Valencia, Spain.

3 Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain

4 Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. Center for Public Health Research (CSISP), Valencia, Spain.

5 CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. Conselleria de Sanidad, Valencia, Spain

6 Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. Center for Public Health Research (CSISP), Valencia, Spain.

Abstract

Indications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary

Keywords

Main Subjects